Want to see RAPP full AI Analyst Report?
RAPP Stock Chart & Stats
$39.71
-$0.34(-1.94%)
At close: 4:00 PM EST
$39.71
-$0.34(-1.94%)
Day’s Range― - ―
52-Week Range$13.43 - $43.76
Previous CloseN/A
Volume10.11K
Average Volume (3M)397.86K
Market Cap
$2.01B
Enterprise Value$1.28B
Total Cash (Recent Filing)$476.78M
Total Debt (Recent Filing)$10.80M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Aug 06, 2026EPS Estimate
-0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.60
Shares Outstanding47,826,927
10 Day Avg. Volume569,027
30 Day Avg. Volume397,861
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-16.18
Enterprise Value/Market Cap0.64
Enterprise Value/Revenue63.92
Enterprise Value/Gross Profit65.53
Enterprise Value/Ebitda-10.82
Forecast
1Y Price Target
$53.71Price Target Upside35.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-3.46
Revenue Forecast (FY)$20.00M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetRapport’s very low debt-to-equity and rebuilt equity base provide durable financial flexibility to fund clinical programs and absorb trial timing variability. This reduces immediate refinancing pressure, lowers interest burden, and supports multi-stage development financing without forcing rapid asset sales or extreme cost cutting.
Differentiated Phase 2a Clinical Data (RAP-219)Follow-up Phase 2a results showing large, sustained seizure reductions and an ~22-day half-life signal meaningful clinical differentiation and favorable pharmacokinetics. Those durable attributes strengthen the rationale for pivotal Phase 3 planning, broaden potential indications, and improve the product’s long-term commercial and regulatory prospects.
Emerging Revenue InflectionThe appearance of TTM revenue after prior zero reflects initial commercialization, milestone, or other non-recurring revenue beginnings and signals the company can generate product-linked cash. Over months this can reduce binary clinical dependency and demonstrates a path—albeit early—toward diversified revenue sources.
Bears Say
High Cash BurnSustained, large negative operating and free cash flow imply the company requires ongoing external funding to progress programs. High burn shortens runway, raises dilution risk, and forces strategic trade-offs on program pacing or partnerships; this is a durable constraint until cash flow turns positive or financing is secured.
Large Net LossesMaterial, persistent net losses reflect heavy R&D and operating investment well beyond current revenue. Until clinical successes convert to approvals or sustained revenue, margins will remain negative, limiting free-cash generation and making profitability a multi-period objective rather than imminent outcome.
Clinical-stage Execution And Commercial UncertaintyAs a clinical-stage biotech, Rapport’s long-term outlook depends on trial results, regulatory approval, and commercial execution. This structural exposure creates binary, high-impact outcomes and sustained capital needs; the business lacks proven commercial operations and remains sensitive to development setbacks.
Rapport Therapeutics, Inc. News
RAPP FAQ
What was Rapport Therapeutics, Inc.’s price range in the past 12 months?
Rapport Therapeutics, Inc. lowest stock price was $13.43 and its highest was $43.76 in the past 12 months.
What is Rapport Therapeutics, Inc.’s market cap?
Rapport Therapeutics, Inc.’s market cap is $2.01B.
When is Rapport Therapeutics, Inc.’s upcoming earnings report date?
Rapport Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 26 days.
How were Rapport Therapeutics, Inc.’s earnings last quarter?
Rapport Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.42 earnings per share for the quarter, beating the consensus estimate of -$0.605 by $0.185.
Is Rapport Therapeutics, Inc. overvalued?
According to Wall Street analysts Rapport Therapeutics, Inc.’s price is currently Undervalued.
Does Rapport Therapeutics, Inc. pay dividends?
Rapport Therapeutics, Inc. does not currently pay dividends.
What is Rapport Therapeutics, Inc.’s EPS estimate?
Rapport Therapeutics, Inc.’s EPS estimate is -0.96.
How many shares outstanding does Rapport Therapeutics, Inc. have?
Rapport Therapeutics, Inc. has 47,826,927 shares outstanding.
What happened to Rapport Therapeutics, Inc.’s price movement after its last earnings report?
Rapport Therapeutics, Inc. reported an EPS of -$0.42 in its last earnings report, beating expectations of -$0.605. Following the earnings report the stock price went up 7.744%.
Which hedge fund is a major shareholder of Rapport Therapeutics, Inc.?
Currently, no hedge funds are holding shares in RAPP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rapport Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$53.71 (35.27% Upside)
$53.71 (35.27% Upside)
Blogger Sentiment
Bullish
RAPP Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.9%
Last 30 Days ▼ 5.8%
Last 30 Days ▼ 5.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
200.14%
12-Months-Change
Fundamentals
Return on Equity
-24.79%
Trailing 12-Months
Asset Growth
64.74%
Trailing 12-Months
Company Description
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
RAPP Stock 12 Month Forecast
Average Price Target
$53.71
▲(35.27% Upside)
Technical Analysis
Ownership Overview
22.51% Insiders
24.40% Mutual Funds
0.03% Other Institutional Investors
44.30% Public Companies and
Individual Investors